- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05445531
Low-field Magnetic Resonance Imaging in Pediatric Post Covid-19 (FASCINATE)
Low-field Magnetic Resonance Imaging to Assess Changes in Pulmonary Function Parameters in Confirmed Pediatric SARS-CoV-2 Infection
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a new coronavirus and identified causative agent of COVID-19 disease. These viruses predominantly cause mild colds, but can sometimes cause severe pneumonia and pulmonary skeletal changes. By low-field gastric magnetic resonance imaging (NF-MRI), only a small number of structural, scarring changes were seen in a preliminary study of pediatric and adolescent patients with past SARS-CoV-2 infection. In contrast, however, extensive changes in ventilation and blood flow function of the lungs were seen.
The long-term consequences and spontaneous progression of these changes on imaging are completely unclear. The aim of this study is to assess the course of these functional lung changes in pediatric and adolescent patients and to validate them with other standard clinical procedures.
Study Overview
Status
Conditions
Detailed Description
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a new coronavirus and identified causative agent of COVID-19 disease. They predominantly cause mild colds but can sometimes cause severe pneumonia and pulmonary skeletal disease. While the molecular basis for the changes in lung tissue or multi-organ involvement have been described, the age-specific long-term consequences, especially in children and adolescents, remain largely unexplained and misunderstood today.
Early publications from the primarily affected Chinese provinces described rather mild, partly asymptomatic courses in children. This is consistent with the observation that the risk of severe COVID-19 disease increases steeply from the age of 70 years, and is also determined by the severity of obesity as well as other risk factors. Developmental expression of tissue factors may be one reason for the relative protection of younger patients from severe courses of the disease.
However, it is now becoming increasingly clear that some individuals with milder initial symptoms of COVID-19 may suffer from variable and persistent symptoms for many months after initial infection - this includes children. A modern low-field MRI is located in Erlangen, Germany. This technique has already been used to demonstrate persistent damage to lung tissue in adult patients after COVID-19. The device with a field strength of 0.55 Tesla (T) currently has the world's largest aperture (and is thus particularly suitable for patients with claustrophobia, among other things), a very quiet operating noise, and lower energy absorption in the tissue due to the weaker magnetic field than MRI scanners with 1.5T or 3T. This allows MRI imaging in a very broad pediatric population without the need for sedation.
To date, no structural changes were revealed by means of this MRI technique - however, large defects in the area of ventilation and blood flow function of the lung are apparent in specific functional sequences. The aim of this study is to assess the course of these functional lung changes in pediatric and adolescent patients and to validate them with other standard clinical procedures.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ferdinand Knieling, MD
- Phone Number: 33118 +49913185
- Email: ferdinand.knieling@uk-erlangen.de
Study Locations
-
-
Bavaria
-
Erlangen, Bavaria, Germany, 91054
- Recruiting
- University Hospital Erlangen
-
Contact:
- Ferdinand Knieling, MD
- Phone Number: 33118 +49913185
- Email: ki-forschung@uk-erlangen.de
-
Principal Investigator:
- Ferdinand Knieling, MD
-
Sub-Investigator:
- Rafael Heiß, MD
-
Sub-Investigator:
- Isabelle Schöffl, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Control arm:
Inclusion Criteria:
- Proof of SARS-CoV-2 infection and at least 2/3 times complete vaccination before infection (at least 14 days) (complete vaccination status according to German recommendations)
- Long Covid criteria not met according to AWMF S1 guideline
Exclusion Criteria:
- Acute SARS-CoV-2 infection and need for isolation
- Necessary quarantine
- Pregnancy, lactation
- Indication of acute infection
- Known pleural or pericardial effusion
- Critical condition (need for respiratory support, ventilation, oxygen administration, shock, symptomatic heart failure)
- Marked thoracic deformities
- Previous lung surgery
- Injuries that do not allow for physical stress testing
- Refusal of MRI imaging
- General contraindications to MRI examinations (e.g., electrical implants such as pacemakers or perfusion pumps, etc.)
- History, clinical, or other suspicion of pulmonary disease
- Current respiratory infection/symptomatology
- Pain leading to respiratory limitation
- Inhaled therapy (e.g., steroids or beta-mimetics)
- Immunosuppression
- Any condition that may lead to respiratory limitation (e.g., pain disorder)
- Obesity (>97% of age percentile)
Recovered arm:
Inclusion Criteria:
- Positive SARS-CoV-2 infection confirmed by PCR
- Long Covid criteria not met according to AWMF S1 guideline
Exclusion Criteria:
- Acute SARS-CoV-2 infection and need for isolation
- Necessary quarantine
- Pregnancy, lactation
- Indication of acute infection
- Known pleural or pericardial effusion
- Critical condition (need for respiratory support, ventilation, oxygen administration, shock, symptomatic heart failure)
- Marked thoracic deformities
- Previous lung surgery
- Injuries that do not allow for physical stress testing
- Refusal of MRI imaging
- General contraindications to MRI examinations (e.g., electrical implants such as pacemakers or perfusion pumps, etc.)
Long Covid arm:
Inclusion Criteria:
- Positive SARS-CoV-2 infection confirmed by PCR
- Long Covid criteria according to AWMF S1 guideline fulfilled
Exclusion Criteria:
- Acute SARS-CoV-2 infection and need for isolation
- Necessary quarantine
- Pregnancy, lactation
- Indication of acute infection
- Known pleural or pericardial effusion
- Critical condition (need for respiratory support, ventilation, oxygen administration, shock, symptomatic heart failure)
- Marked thoracic deformities
- Previous lung surgery
- Injuries that do not allow for physical stress testing
- Refusal of MRI imaging
- General contraindications to MRI examinations (e.g., electrical implants such as pacemakers or perfusion pumps, etc.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control
Proof of SARS-CoV-2 infection and at least 2/3 times complete vaccination before infection (at least 14 days) (complete vaccination status according to STIKO, German vaccination committee)
|
Functional and morphologic imaging of the lungs
Other Names:
Imaging of nailfold microvasculature
Cardiopulmonary exercise testing
High-throughput measurement of cell deformability and physical properties
Other Names:
|
Active Comparator: Recovered
Positive SARS-CoV-2 infection confirmed by PCR; Long Covid criteria according to AWMF S1 guideline not fulfilled.
|
Functional and morphologic imaging of the lungs
Other Names:
Imaging of nailfold microvasculature
Cardiopulmonary exercise testing
High-throughput measurement of cell deformability and physical properties
Other Names:
|
Experimental: Long Covid
Positive SARS-CoV-2 infection confirmed by PCR; Long Covid criteria according to AWMF S1 guideline fulfilled.
|
Functional and morphologic imaging of the lungs
Other Names:
Imaging of nailfold microvasculature
Cardiopulmonary exercise testing
High-throughput measurement of cell deformability and physical properties
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional lung assessment (LF-MRI)
Time Frame: Baseline compared to 6 months
|
Change in functional lung parameters
|
Baseline compared to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Morphologic lung assessment (LF-MRI)
Time Frame: Baseline compared to 6 months
|
Morphologic changes in lung parenchyma
|
Baseline compared to 6 months
|
Cardiological functional diagnostics (VO2)
Time Frame: Baseline compared to 6 months
|
Oxygen uptake (VO2)
|
Baseline compared to 6 months
|
Cardiological functional diagnostics (VO2max)
Time Frame: Baseline compared to 6 months
|
Peak oxygen uptake (VO2max)
|
Baseline compared to 6 months
|
Cardiological functional diagnostics (VT2)
Time Frame: Baseline compared to 6 months
|
Ventilatory anaerobic threshold (VT2)
|
Baseline compared to 6 months
|
Cardiological functional diagnostics (VCO2)
Time Frame: Baseline compared to 6 months
|
Carbon dioxide output (VCO2)
|
Baseline compared to 6 months
|
Cardiological functional diagnostics (HR)
Time Frame: Baseline compared to 6 months
|
Heart rate (HR)
|
Baseline compared to 6 months
|
Cardiological functional diagnostics (HRR)
Time Frame: Baseline compared to 6 months
|
Heart Rate Reserve (HRR)
|
Baseline compared to 6 months
|
Cardiological functional diagnostics (Breath rate at VAT)
Time Frame: Baseline compared to 6 months
|
Breath rate at VAT
|
Baseline compared to 6 months
|
Cardiological functional diagnostics (BRR)
Time Frame: Baseline compared to 6 months
|
Breath rate reserve (BRR)
|
Baseline compared to 6 months
|
Cardiological functional diagnostics (VE)
Time Frame: Baseline compared to 6 months
|
Minute ventilation (VE)
|
Baseline compared to 6 months
|
Cardiological functional diagnostics (O2Pulse)
Time Frame: Baseline compared to 6 months
|
O2Pulse
|
Baseline compared to 6 months
|
Cardiological functional diagnostics (HRV)
Time Frame: Baseline compared to 6 months
|
Heart rate variability (HRV)
|
Baseline compared to 6 months
|
Cardiological functional diagnostics (Borg Scale)
Time Frame: Baseline compared to 6 months
|
Exercise capacity nach Borg Scale
|
Baseline compared to 6 months
|
Cardiological functional diagnostics (BGA)
Time Frame: Baseline compared to 6 months
|
Capillary blood gas and lactate (BGA)
|
Baseline compared to 6 months
|
Nailfold capillaroscopy (capillaries)
Time Frame: Baseline compared to 6 months
|
Number of capillaries in first row
|
Baseline compared to 6 months
|
Nailfold capillaroscopy (first row)
Time Frame: Baseline compared to 6 months
|
Number of capillaries in first row
|
Baseline compared to 6 months
|
Nailfold capillaroscopy (morphology)
Time Frame: Baseline compared to 6 months
|
Morphology of capillaries
|
Baseline compared to 6 months
|
Blood sample (antibodies)
Time Frame: Baseline compared to 6 months
|
SARS-CoV2-antibodies
|
Baseline compared to 6 months
|
Blood sample (auto antibodies)
Time Frame: Baseline compared to 6 months
|
Autoantibodies against G-protein receptors
|
Baseline compared to 6 months
|
Blood sample (RT-DC)
Time Frame: Baseline compared to 6 months
|
Realtime deformability cytometry
|
Baseline compared to 6 months
|
Blood sample (Blood count)
Time Frame: Baseline compared to 6 months
|
Blood count
|
Baseline compared to 6 months
|
Blood sample (IL-6)
Time Frame: Baseline compared to 6 months
|
Interleukin-6 (IL-6)
|
Baseline compared to 6 months
|
Blood sample (CrP)
Time Frame: Baseline compared to 6 months
|
C-reactive proteine (CrP)
|
Baseline compared to 6 months
|
Blood sample (Calpro)
Time Frame: Baseline compared to 6 months
|
Calprotectin (Calpro)
|
Baseline compared to 6 months
|
Blood sample (Coagulation)
Time Frame: Baseline compared to 6 months
|
Coagulation factors (Coagulation)
|
Baseline compared to 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ferdinand Knieling, MD, University Hospital Erlangen
Publications and helpful links
General Publications
- Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C, Liu H, Liu D, Shao J, Peng X, Yang Y, Liu Z, Xiang Y, Zhang F, Silva RM, Pinkerton KE, Shen K, Xiao H, Xu S, Wong GWK; Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children. N Engl J Med. 2020 Apr 23;382(17):1663-1665. doi: 10.1056/NEJMc2005073. Epub 2020 Mar 18. No abstract available.
- Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021 Jan;27(1):28-33. doi: 10.1038/s41591-020-01202-8. Epub 2021 Jan 13.
- Sajuthi SP, DeFord P, Li Y, Jackson ND, Montgomery MT, Everman JL, Rios CL, Pruesse E, Nolin JD, Plender EG, Wechsler ME, Mak ACY, Eng C, Salazar S, Medina V, Wohlford EM, Huntsman S, Nickerson DA, Germer S, Zody MC, Abecasis G, Kang HM, Rice KM, Kumar R, Oh S, Rodriguez-Santana J, Burchard EG, Seibold MA. Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium. Nat Commun. 2020 Oct 12;11(1):5139. doi: 10.1038/s41467-020-18781-2.
- Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, Cao Y, Yousif AS, Bals J, Hauser BM, Feldman J, Muus C, Wadsworth MH 2nd, Kazer SW, Hughes TK, Doran B, Gatter GJ, Vukovic M, Taliaferro F, Mead BE, Guo Z, Wang JP, Gras D, Plaisant M, Ansari M, Angelidis I, Adler H, Sucre JMS, Taylor CJ, Lin B, Waghray A, Mitsialis V, Dwyer DF, Buchheit KM, Boyce JA, Barrett NA, Laidlaw TM, Carroll SL, Colonna L, Tkachev V, Peterson CW, Yu A, Zheng HB, Gideon HP, Winchell CG, Lin PL, Bingle CD, Snapper SB, Kropski JA, Theis FJ, Schiller HB, Zaragosi LE, Barbry P, Leslie A, Kiem HP, Flynn JL, Fortune SM, Berger B, Finberg RW, Kean LS, Garber M, Schmidt AG, Lingwood D, Shalek AK, Ordovas-Montanes J; HCA Lung Biological Network. Electronic address: lung-network@humancellatlas.org; HCA Lung Biological Network. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell. 2020 May 28;181(5):1016-1035.e19. doi: 10.1016/j.cell.2020.04.035. Epub 2020 Apr 27.
- Huang J, Hume AJ, Abo KM, Werder RB, Villacorta-Martin C, Alysandratos KD, Beermann ML, Simone-Roach C, Lindstrom-Vautrin J, Olejnik J, Suder EL, Bullitt E, Hinds A, Sharma A, Bosmann M, Wang R, Hawkins F, Burks EJ, Saeed M, Wilson AA, Muhlberger E, Kotton DN. SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response. Cell Stem Cell. 2020 Dec 3;27(6):962-973.e7. doi: 10.1016/j.stem.2020.09.013. Epub 2020 Sep 18.
- Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, Zheng M, Sundaram B, Banoth B, Malireddi RKS, Schreiner P, Neale G, Vogel P, Webby R, Jonsson CB, Kanneganti TD. Synergism of TNF-alpha and IFN-gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell. 2021 Jan 7;184(1):149-168.e17. doi: 10.1016/j.cell.2020.11.025. Epub 2020 Nov 19.
- Schuler BA, Habermann AC, Plosa EJ, Taylor CJ, Jetter C, Negretti NM, Kapp ME, Benjamin JT, Gulleman P, Nichols DS, Braunstein LZ, Hackett A, Koval M, Guttentag SH, Blackwell TS, Webber SA, Banovich NE; Vanderbilt COVID-19 Consortium Cohort; Human Cell Atlas Biological Network, Kropski JA, Sucre JM. Age-determined expression of priming protease TMPRSS2 and localization of SARS-CoV-2 in lung epithelium. J Clin Invest. 2021 Jan 4;131(1):e140766. doi: 10.1172/JCI140766.
- Heiss R, Grodzki DM, Horger W, Uder M, Nagel AM, Bickelhaupt S. High-performance low field MRI enables visualization of persistent pulmonary damage after COVID-19. Magn Reson Imaging. 2021 Feb;76:49-51. doi: 10.1016/j.mri.2020.11.004. Epub 2020 Nov 18.
- Shelmerdine SC, Lovrenski J, Caro-Dominguez P, Toso S; Collaborators of the European Society of Paediatric Radiology Cardiothoracic Imaging Taskforce. Coronavirus disease 2019 (COVID-19) in children: a systematic review of imaging findings. Pediatr Radiol. 2020 Aug;50(9):1217-1230. doi: 10.1007/s00247-020-04726-w. Epub 2020 Jun 18.
- Duan YN, Zhu YQ, Tang LL, Qin J. CT features of novel coronavirus pneumonia (COVID-19) in children. Eur Radiol. 2020 Aug;30(8):4427-4433. doi: 10.1007/s00330-020-06860-3. Epub 2020 Apr 14.
- Steinberger S, Lin B, Bernheim A, Chung M, Gao Y, Xie Z, Zhao T, Xia J, Mei X, Little BP. CT Features of Coronavirus Disease (COVID-19) in 30 Pediatric Patients. AJR Am J Roentgenol. 2020 Dec;215(6):1303-1311. doi: 10.2214/AJR.20.23145. Epub 2020 May 22.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-77-Bm
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Low-field magnetic resonance imaging
-
University of Erlangen-Nürnberg Medical SchoolRecruitingCovid19 | Sars-CoV-2 Infection | Lung FibrosisGermany
-
Mclean HospitalStanley Medical Research InstituteTerminatedDepression | Bipolar Disorder | Bipolar DepressionUnited States
-
University of Erlangen-Nürnberg Medical SchoolRecruitingHodgkin Disease | Acute Lymphoblastic Leukemia | Allogeneic Stem Cell TransplantationGermany
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Terminated
-
University of AberdeenRecruitingMyocardial InfarctionUnited Kingdom
-
Weill Medical College of Cornell UniversityCompletedTreatment Resistant DepressionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingProstate Adenocarcinoma | Prostate CarcinomaUnited States
-
University of California, San FranciscoTerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States